3 completed, 2 active not recruiting, 2 withdrawn, 1 recruiting. 6 Phase 2, 2 Early Phase 1, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Early Phase 1 | 2 | Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Unresectable Soft Tissue Sarcoma: new trials by email Literature Review of Unresectable Soft Tissue Sarcoma trials Research Report on Unresectable Soft Tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma Antibody-drug conjugate (ADC) - Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma | Phase 1 / Phase 2 | Recruiting | Adcendo ApS | 270 | 2025-06-05 | 2026-09-11 |
| Gemcitabine With Ascorbate Including Adolescents Ascorbate, Gemcitabine - Soft Tissue Sarcoma, Bone Sarcoma | Early Phase 1 | Withdrawn | David Dickens | 2023-01-01 | 2023-02-22 | |
| Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) Ascorbate - Sarcoma, Soft Tissue Sarcoma | Early Phase 1 | Active not recruiting | University of Iowa | 30 | 2020-11-24 | 2026-05-22 |
| Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Cabozantinib, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 96 | 2020-01-14 | 2026-05-01 |
| Gemcitabine Plus Ascorbate for Sarcoma in Adults Ascorbate, Gemcitabine - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Terminated | Mohammed Milhem, MBBS | 10 | 2018-07-11 | 2020-12-10 |
| Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma Biopsy, Laboratory Biomarker Analysis, Trabectedin - Myxoid Liposarcoma, Round Cell Liposarcoma | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2018-06-19 | 2019-09-10 | |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 164 | 2015-08-13 | 2023-10-17 |
| Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma INNO-206, Doxorubicin - Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma | Phase 2 | Completed | ImmunityBio, Inc. | 126 | 2012-01-11 | 2024-05-29 |
Sarcoma (9) · Bone Neoplasms (4) · Histiocytoma, Malignant Fibrous (2) · Liposarcoma (2) · Dermatofibrosarcoma (1) · Disorders of Sex Development (1) · Fibrosarcoma (1) · Hemangiosarcoma (1) · Leiomyosarcoma (1) · Liposarcoma, Myxoid (1) · Neoplasm Metastasis (1) · Neurofibrosarcoma (1) · Sarcoma, Synovial (1)
Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Connective and Soft Tissue (9) · Bone Diseases (4) · Musculoskeletal Diseases (4) · Neoplasms by Site (4) · Neoplasms, Adipose Tissue (3) · Histiocytoma (2) · Neoplasms, Connective Tissue (2) · Neoplasms, Fibrous Tissue (2) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Ascorbic Acid (2) · Doxorubicin (2) · Gemcitabine (2) · Biopsy (1) · CTLA-4 Antigen (1) · DOXO-EMCH (1) · Immunoconjugates (1) · Ipilimumab (1) · Nivolumab (1) · Temozolomide (1) · Trabectedin (1) · cabozantinib (1) · ribociclib (1)
Adcendo ApS (1) · City of Hope Medical Center (1) · David Dickens (1) · Fred Hutchinson Cancer Center (1) · ImmunityBio, Inc. (1) · Mohammed Milhem, MBBS (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1) · University of Iowa (1)
United States (9) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Romania (1) · Russia (1) · Ukraine (1) · United Kingdom (1)
Daniel Levitt, M.D., Ph.D. (1) · David Dickens, MD, FAAP (1) · Janet Yoon, MD (1) · John Rieth, MD (1) · Lara E Davis (1) · Sandra P D'Angelo (1) · Sant Chawla, M.D. (1) · Seth Pollack (1) · Varun Monga, MD (1)
PMID 26378637, PMID 29370992, PMID 39343511, PMID 41554272
P30CA015704 (1), P30CA060553 (1), U10CA180821 (1)